Independent Franchise Partners LLP raised its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 7.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,467,647 shares of the company’s stock after buying an additional 104,218 shares during the period. DENTSPLY SIRONA comprises approximately 0.9% of Independent Franchise Partners LLP’s portfolio, making the stock its 21st largest position. Independent Franchise Partners LLP’s holdings in DENTSPLY SIRONA were worth $87,222,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Contravisory Investment Management Inc. boosted its position in DENTSPLY SIRONA by 8.9% in the third quarter. Contravisory Investment Management Inc. now owns 3,108 shares of the company’s stock valued at $185,000 after buying an additional 254 shares during the period. Evercore Wealth Management LLC boosted its position in DENTSPLY SIRONA by 12.6% in the second quarter. Evercore Wealth Management LLC now owns 3,204 shares of the company’s stock valued at $199,000 after buying an additional 358 shares during the period. Mizuho Asset Management Co. Ltd. boosted its position in DENTSPLY SIRONA by 170.4% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,228 shares of the company’s stock valued at $200,000 after buying an additional 2,034 shares during the period. Harbour Capital Advisors LLC purchased a new position in DENTSPLY SIRONA during the second quarter valued at approximately $217,000. Finally, MAI Capital Management boosted its position in DENTSPLY SIRONA by 10.0% in the third quarter. MAI Capital Management now owns 3,862 shares of the company’s stock valued at $230,000 after buying an additional 351 shares during the period. 93.41% of the stock is owned by institutional investors and hedge funds.
Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) opened at 56.55 on Thursday. DENTSPLY SIRONA Inc. has a 52-week low of $53.43 and a 52-week high of $65.83. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of 29.55 and a beta of 1.23. The company’s 50-day moving average price is $58.55 and its 200-day moving average price is $60.07.
DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Friday, November 4th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.03. The firm earned $954.20 million during the quarter, compared to the consensus estimate of $967.68 million. DENTSPLY SIRONA had a net margin of 11.15% and a return on equity of 8.04%. The business’s revenue for the quarter was up 47.0% compared to the same quarter last year. During the same period last year, the business posted $0.66 earnings per share. Equities research analysts forecast that DENTSPLY SIRONA Inc. will post $2.77 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 13th. Shareholders of record on Friday, December 30th were given a dividend of $0.0775 per share. The ex-dividend date of this dividend was Wednesday, December 28th. This is an increase from DENTSPLY SIRONA’s previous quarterly dividend of $0.07. This represents a $0.31 annualized dividend and a yield of 0.55%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is 15.98%.
Several equities analysts have commented on XRAY shares. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, January 9th. Morgan Stanley raised DENTSPLY SIRONA from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $65.00 to $69.00 in a report on Tuesday, November 1st. They noted that the move was a valuation call. JPMorgan Chase & Co. assumed coverage on DENTSPLY SIRONA in a research note on Thursday, September 22nd. They issued a “neutral” rating and a $65.00 price objective on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $67.00 price objective (down from $69.00) on shares of DENTSPLY SIRONA in a research note on Tuesday, October 4th. Finally, Barrington Research upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $63.00 price objective on the stock in a research note on Monday, December 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $66.78.
In other DENTSPLY SIRONA news, CEO James G. Mosch sold 30,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $60.93, for a total transaction of $1,852,272.00. Following the completion of the sale, the chief executive officer now directly owns 75,283 shares in the company, valued at $4,586,993.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.20% of the company’s stock.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc, formerly DENTSPLY International Inc, designs, develops, manufactures and markets a range of consumable dental products for the professional dental market. The Company also manufactures and markets consumable medical device products consisting mainly of urological catheters and certain surgical products.
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).